



Interface Prescribing & New Therapies Subgroup



Date of original recommendation: 16th February 2010
Date Re-reviewed: 25th September 2012.

Tolvaptan (Samsca®▼) for treatment of hyponatraemia caused by SIADH

The New Therapies Subgroup discussed the above drug at a meeting on 16th February 2010. The recommendation of this subgroup is as follows:*

The New Therapies Subgroup of the GMMMG considered the use of Tolvaptan (Samsca®▼) for treatment of hyponatraemia caused by SIADH.

The group recommends that use of tolvaptan should be restricted to adult patients who have frequent hospital admissions and in whom fluid restriction has failed.

Two placebo controlled trials showed that tolvaptan was effective in increasing serum sodium levels during the first four days and after the full thirty days of therapy.

The group recommends that due to the specialist nature of the condition initiation and monitoring (sodium concentrations and volume status) of the drug should be remain within secondary care.

Review date: September 2014

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk/benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.